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Abstract
Background: Therapeutic drug monitoring (TDM) aid therapeutic decision making in patients with inflammatory
bowel disease (IBD) who lose response to anti-TNF therapy. Our aim was to evaluate the frequency and predictive
factors of loss of response (LOR) to adalimumab using TDM in IBD patients.
Methods: One hundred twelve IBD patients (with 214 TDM measurements, CD/UC 84/28, male/female 50/62,
mean age CD/UC: 36/35 years) were enrolled in this consecutive cohort from two referral centres in Hungary.
Demographic data were comprehensively collected and harmonized monitoring strategy was applied. Previous and
current therapy, laboratory data and clinical activity were recorded at the time of TDM. Patients were evaluated
either at the time of suspected LOR or during follow-up. TDM measurements were determined by commercial
ELISA (LISA TRACKER, Theradiag, France).
Results: Among 112 IBD patients, LOR/drug persistence was 25.9%/74.1%. The cumulative ADA positivity (>10 ng/mL)
and low TL (<5.0 μg/mL) was 12.1% and 17.8% after 1 year and 17.3% and 29.5% after 2 years of adalimumab therapy.
Dose intensification was needed in 29.5% of the patients. Female gender and ADA positivity were associated with LOR
(female gender: p < 0.001, OR:7.8 CI 95%: 2.5–24.3, ADA positivity: p = 0.007 OR:3.6 CI 95%: 1.4–9.5).
Conclusions: ADA development, low TL and need for dose intensification were frequent during adalimumab therapy
and support the selective use of TDM in IBD patients treated with adalimumab. ADA positivity and gender were
predictors of LOR.
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Background
Inflammatory bowel diseases (IBD) are chronic condi-
tions that significantly influence quality of life (QoL) and
can lead to disability and complications. Anti-tumor
necrosis factor alfa (anti-TNF) therapy is effective in
IBD, demonstrating improvement in patients’ QoL, lead-
ing to clinical remission and mucosal healing, reducing
the need for surgery and hospitalizations. However,
approximately 10-30% of the patients do not respond to
the initial treatment and app. one third of the patients
lose response to anti-TNF therapy over time [1]. There
are several possible causes for loss of response (LOR) to
anti-TNF therapy, although one of the most common is
decreased drug levels due to the development of anti-
drug antibodies (ADA). ADAs can neutralize the anti-
TNF drug connecting to the Fab segment of the protein
or bind only the anti-TNF molecule promoting the for-
mation of immune complexes both of them leading to
increased clearance of the anti-TNF drug through the
reticulo-endothelial system. This results in altered drug
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pharmacokinetics and in a reduction of therapeutic effi-
cacy [2]. Therapeutic drug monitoring (TDM), measur-
ing drug trough levels (TL) and ADA levels may aid the
therapeutic decision in patients who lose response to
anti-TNF therapy. Several studies have indicated that
TDM based therapy may predict the loss of response to
infliximab therapy [3, 4] and TDM based dosing of
infliximab therapy can result in economic benefit [5].
However, less data is available on the relevance of TDM
assessment during adalimumab therapy, whether TLs and
ADA levels are strongly associated with disease outcome
remains questionable. Although correlation between the
adalimumab drug concentration and clinical outcome was
reported, the role of routine TDM assessment during adali-
mumab therapy remained unclear [6]. In the post-hoc ana-
lysis of the CLinical Assessment of Adalimumab Safety and
Efficacy Studied as Induction Therapy in Crohn’s Disease
(CLASSIC) I/II trial, a positive correlation between serum
adalimumab concentrations and clinical remission was re-
ported, although it was not able to delineate a reliable
therapeutic cut-off for adalimumab therapy [7]. More re-
cent studies suggested that the optimal therapeutic TL for
adalimumab is at around 5 μg/mL [8–10], while different
reports exist depending on the measurement methods [2].
The aim of the present study was to evaluate the fre-
quency and predictive factors of loss of response to ada-
limumab therapy and the role of TDM to predict LOR
in adalimumab treated IBD patients.
Methods
Patients were consecutively enrolled in this cohort be-
tween 2014 November and 2016 June from two referral
IBD centres in Hungary. Demographic data were compre-
hensively collected and a harmonized monitoring strategy
(including regular assessment of disease activity/bio-
markers at start of the adalimumab therapy and during
follow-up) was applied as requested by the Hungarian Na-
tional Health Fund [11]. Previous and current therapy, la-
boratory data and clinical activity at the time of TDM
were recorded. Adalimumab was administered at an in-
duction dose of 160/80 mg and then at standard doses of
40 mg every other week. Dose intensification was defined
as administration of 40 mg every week. Samples for TDM
were collected right before routine adalimumab injection.
Disease location and disease behavior in Crohn’s disease
(CD) and disease extent in ulcerative colitis (UC) were
classified according to the Montreal classification [12].
Patients were evaluated either at the time of suspected
LOR (based on clinical evaluation) or during regular
follow-up visits with TDM measurement using a conven-
tional and bridging enzyme-linked immunosorbent (ELISA)
assay (LISA TRACKER, Theradiag, France). For the meas-
urement of ADA levels, the bridging ELISA method uses a
double-antigen bridge: ADAs create a bridge between
adalimumab immobilized on the plate and adalimumab
enzyme-linked conjugate. ELISA measurements were per-
formed at the Department of Laboratory Medicine, Sem-
melweis University, Budapest. All ELISA kit was validated
for accuracy and reproducibility of TDM for adalimumab
(Theradiag, France). The limit of detection for the adalimu-
mab drug level is 0.1 μg/mL determined by the manufac-
turer of the assay. The optimal therapeutic cut-off value for
low adalimumab TL was defined as 5 μg/ml, in concord-
ance with previous studies. The standard cut-off value of
detectable ADA levels by the assay was 10 ng/ml. To better
stratify ADA positive patients we defined ADA levels more
than 200 ng/ml as ‘high’ADA level. Transient ADA was de-
fined when the ADA positivity disappeared on the next
TDM of the patient. In CD, clinical remission was defined
as Crohn’s Disease Activity Index (CDAI) < 150 points or
no fistula drainage as assessed by the Fistula Drainage
Assessment, while clinical response was defined as a de-
crease in CDAI with more than 70 points or at least 50%
reduction in the number and production of draining fistulas
[13]. In patients with UC, the partial Mayo score (pMayo)
was used: patients with more than a 3 point reduction was
defined as responder, while patients with pMayo <3 were
considered as being in remission [14]. LOR was defined as
discontinuation of adalimumab therapy. Patients with
ongoing symptoms despite dose intensification were dis-
continued from further adalimumab therapy, and consid-
ered to have loss of response. Patients regaining response
after dose intensification were considered to have sustained
clinical benefit.
Statistical considerations
For categorical data frequency distributions were analysed,
for continuous variables mean and SD were calculated.
Chi-squared test was used to evaluate differences within
subgroups of patients and binary logistic regression was
performed for multivariate analysis (variables with a p < 0.2
in univariate analysis were included in the multivariate
models). For time-dependent outcomes Kaplan-Meier
curves were plotted was performed. A p-value of <0.05 was
regarded as statistically significant. Statistical analysis was
performed using the SPSS software v. 20.0 (Chicago, IL).
Ethical statement
The study complies with the principles of the Declaration
of Helsinki. The study protocol was approved by the
Semmelweis University Regional and Institutional Committee
of Science and Research Ethics. (29772-2/2014/EKU).
Results
Patient characteristics
One hundred twelve IBD patients (with 214 TDM mea-
surements, CD/UC 84/28, male/female 50/62, mean age
CD/UC: 36/35 years (y) (SD: 10.9/11.2 y) were enrolled
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in this consecutive cohort. Detailed patient characteris-
tics are shown in Table 1.
The frequency of previous and current 5-aminosalicylate
(5-ASA), steroid and azathioprine (AZA) exposure were
85.6%/26.8%, 92.9%/6.3% and 77.7%/44.7%. Previous anti-
TNF therapy was present in 65.2% (CD 60.2%, UC 82.1%)
in the IBD cohort. Mean duration of adalimumab therapy
during follow-up was 157.8/70.1 weeks (SD: 101.7/
58.0 weeks) in CD/UC.
Frequency of low TL and ADA development
Among 112 IBD patients, frequency of ADA positivity
was 20.5% (23/112). Among the ADA positive patients, 7
patients had high ADA titres (>200 ng/ml) and 7 patients
had only transient ADA positivity (6.3%). Frequency of
low TL (<5.0 μg/mL) was 31.3% (35/112). Cumulative
ADA positivity was 12.1% and low TL rate was 17.8% after
1 year, and 17.3% and 29.5%, respectively after 2 years of
adalimumab therapy. Concomitant immunomodulatory
(IM) therapy was not associated with ADA positivity
(p = 0.156). The combination of normal TL and no ADA,
normal TL and ADA positivity, low TL and no ADA, and
low TL and ADA positivity were observed in 58%, 10.7%,
21.4% and 9.8% at TDM measurement (Table 2).
Frequency of dose intensification and loss of response
Dose intensification was needed in 29.5% of patients
and 25.9% of the patients had loss of response during
the follow-up. The rate of LOR was similar in the two
different IBD centres (25.4% and 26.5%). In Kaplan-
Meier analysis, probability of dose intensification and
LOR was 19.7% and 17.5% in the first year and 30%
and 18.8% in the second year of adalimumab therapy
(Figs. 1 and 2).
Predictors for dose intensification, loss of response and
TDM levels
Though the association between low TL and ADA posi-
tivity was statistically not significant, the trend towards
an association is clear (47.8% vs. 27%, p = 0.054, OR: 0.4
CI 95%: 0.2–1.0), furthermore this difference was signifi-
cant when analysing patients with low and high ADA
titre separately. Rate of low TL in patients with high
ADA was 85.7%, while it was 28.6% in patients with low
ADA and 27.5% in ADA negative patients (p = 0.006).
There was no association between TL and LOR.
ADA positivity was significantly associated with LOR
(p = 0.007, ADA positivity in LOR 47.8% vs. 20.2%, OR:
3.6, CI 95%: 1.4 – 9.5), even if patients with low or high
titre ADA (LOR rates in high ADA: 42.9%, low ADA:
50.0%, no ADA: 20.9%, p = 0.039, OR was not available)
were analysed separately. The association was significant
in CD with a similar trend in UC patients (CD: 52.9% vs.
23.9%, p = 0.019, OR: 3.6, CI 95%: 1.2–10.8, UC: 33.3%
vs. 9%, p = 0.133, OR: 5.0 CI 95%: 0.5–46.7).
Transient ADA was marginally associated with LOR
(p = 0.051, OR: 4.3, CI 95%: 0.9–20.4).
LOR was more frequent among patients with dose
intensification (45.5% vs. 17.7%, p = 0.002, OR: 3.869, CI
95%: 1.579–9.479), especially in CD (51.9% vs. 19.3%,
Table 1 Patient characteristics
CD UC
Patients number (n = 112) 84 28
Males/females 39/45 (46%/54%) 11/17 (39%/60%)
Mean age at TDM (SD) 36 years (10.9) 35 years (11.2)
Mean duration of adalimumab therapy (SD) 157.8 weeks (101.7) 70.1 weeks (58.0)
Age at onset (<16y/17-40y/>40y) 13/64/7 -
Localisation of Crohn’s disease (ileal/colon/ileocolon/upper GI/ileocolon + upper GI) 13/16/47/2/5 -
Extension of colitis (proctitis/left sided/extensive) - 0/19/9
Behaviour of CD (inflammatory/stricturing/penetrating/strict. + pen.) 29/18/27/10 -
Perianal disease in CD 42/84 (50%) -
Previous surgery 43/84 (48.8%) 0/28 (0%)
Smoking (yes/no/previous) 44/24/16 19/2/7
Previous 5-ASA 69/84 (82.1%) 26/28 (93%)
Previous steroid 76/84 (90.5%) 28/28 (100%)
Previous/concomitant AZA 67/84 (80%)/42/84 (50%) 20/28 (71.4%)/2/28 (28.6%)
Previous anti-TNF 50/84 (60.2%) 23/28 (82%)
Previous IFX/ADM/both 38/5/7 22/1/0
(CD Crohn’s disease, UC Ulcerative colitis, SD Standard deviation, TDM Therapeutic drug monitoring, GI Gastrointestinal, 5-ASA 5-aminosalycilate, AZA Azathioprine,
anti-TNF Anti-tumor necrosis factor, IFX Infliximab, ADM Adalimumab)
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p = 0.002, OR: 4.503 CI95%: 1.655–12.258) with the
same trend in UC.
There was a significant association between LOR and fe-
male gender (86.2% vs. 44.6%, p < 0.001, OR: 7.8 CI 95%:
2.5–24.3) both in CD and UC. In a sensitivity analysis, re-
sults remained similar if the data from the two centres
were analysed separately. In contrast, there was no associ-
ation between female gender and dose intensification, low
TL or ADA positivity.
Gender (p < 0.001, OR: 9.1, 95% CI: 2.7–30.5) and ADA
positivity (p = 0.007, OR: 4.7, 95% CI: 1.5–14.3) remained
independent predictors of LOR in a multivariate analysis.
We did not find any association between previous
anti-TNF therapy and LOR or ADA status.
Finally, dose intensification was associated with need
of steroid therapy in patients with CD (40.7% vs. 19.6%,
p = 0.04, OR: 2.8, CI 95%: 1.0–7.7).
Discussion
Results from the present study suggest that ADA devel-
opment, low TL and need for dose intensification are
frequent during adalimumab therapy and support the
use of selected TDM assessment in IBD patients during
adalimumab therapy.
Need for dose intensification and frequency of LOR
was 19.7% and 17.5% after 1 year and 30% and 18.8%
after 2 years of adalimumab therapy. These results are in
concordance with the review of Billioud et al. showing
that the mean percentage of LOR and dose intensifica-
tion was 18.2% and 37% with an annual risk of 20.3%
and 24.8% per patient year among primary responders to
adalimumab [15]. Nevertheless, in a follow-up study
from Leuven, 65.4% of adalimumab treated patients with
previous failure of infliximab therapy needed dose in-
tensification and 38.5% eventually stopped adalimumab
therapy mainly due to LOR [16]. In this study, LOR was
more frequent in patients with low TL and high ADA
levels during long-term therapy but no predictors for
short term clinical response were detected [14].
In the present study, approximately one third of the
patients had low TL and 20.5% had ADA positivity.
Patients with high ADA titres (>200 ng/mL) had low TL
in 85%. Despite of ADA development, low TL was not
Table 2 The combination of ADA and TL status
Normal TL Low TL
ADA negative 58% 21.4%
ADA positive 10.7% 9.8%
(ADA Anti-drug antibody, TL Trough level)
Fig. 1 Probability of dose intensification in Kaplan-Meier analysis
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associated with LOR. This suggests that primarily ADA
positivity should be considered as an indicator for treat-
ment failure. Similarly, Roblin et al. suggested that low
TL without ADA can be overcome by dose optimization
with a high rate of clinical response (67%) after dose
optimization and is not leading per se to LOR. In con-
trast, low TL with detectable ADA is associated with
treatment failure, and switching to another anti-TNF or
other therapeutic class should be considered [17].
Additional articles also suggested that the development
of ADA is one of the most important mechanisms of
underlying LOR, and routine TDM assessment may help
improving patient outcomes. In an Italian study, low TL
and ADA positivity correlated with clinical and endo-
scopic recurrence also in postoperative CD patients
[18]. Finally, in a French study, adalimumab TL and dur-
ation of treatment were associated independently with
mucosal healing, while adalimumab TL, ADA positivity,
duration of treatment and adalimumab dose, but not
CRP level were associated independently with clinical re-
mission in multivariate analysis [8].
More than half of our patients received another anti-
TNF agent previously (previous IFX rate: 53% in CD,
78% in UC) in the present study. We did not find any
association between previous anti-TNF therapy and LOR
or ADA status, however the proportion of patients with
previous anti-TNF exposure was very high (74/112). In
contrast, in the study of Yarur et al., detectable ADA to
adalimumab was associated with low adalimumab TL,
previous infliximab use, macroscopic mucosal inflamma-
tion and need for corticosteroids [19]. Similarly, the
positivity rate for ADA to adalimumab was significantly
higher in patients who lost response to infliximab (50%)
than in those naive to anti-TNFs (12.5%) [10].
Concomitant immunomodulatory (IM) therapy was
not associated with ADA positivity, in line with previous
studies [9, 13, 20]. Few studies reported a benefit of par-
allel IMs during adalimumab therapy. In a Belgian study,
time to dose escalation was longer in patients who were
treated with IMs, while Yarur et al. reported that com-
bination therapy of adalimumab and IM yielded a higher
mean level of serum adalimumab compared with mono-
therapy (14 μg/mL vs 9 μg/mL; p = 0.026) [14, 17].
In the present study, there was an association between
LOR and female gender both in CD and UC, even when
data from the two referral centres were analysed separately.
We did not find gender-related differences in other parame-
ters (e.g. TL, ADA, and severity of disease, pervious and
current therapy). In a previous retrospective study by Cohen
et al. [21], gender was also associated with dose escalation
during adalimumab therapy. Gender related differences
were also reported in the rheumatology literature [22, 23].
Fig. 2 Probability of LOR in Kaplan-Meier analysis (LOR: loss of response)
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Low adalimumab TL was defined as <5 μg/mL, in con-
cordance with previous studies. However, reported cut-
off values vary. Mazor et al. identified a drug TL of
5.85 μg/mL as the optimal cut-off for predicting remis-
sion (defined as asymptomatic patients with normal
CRP) in CD [9]. In a Japanese study a TL of 5.9 μg/ml
was identified to best predict normal CRP in a receiver
operator curve (ROC) analysis [10]. Presence of ADA or
a serum drug concentration lower than 5 μg/mL was
associated with worse self-reported disease symptoms
and elevated CRP levels [14, 17]. In contrast, Ungar
et al. reported that serum levels of 8–12 μg/mL for
adalimumab were required to achieve mucosal healing
in patients with IBD. Adalimumab TL higher than
7.1 μg/mL predicted MH with 85% specificity in ROC
analysis [20].
Current tests for anti-TNF and ADA concentrations
are mostly based on enzyme immunoassays. For existing
commercially available assays for antibodies, the pres-
ence of drug generally interferes with the detection of
ADAs. All ADA assays are drug-sensitive to some extent
because most assays use the drug itself as labeled detect-
ing antibody. Newer assays, based on high-performance
liquid chromatography or the pH shift-anti-idiotype
method, which can detect ADAs in the presence of cir-
culating drug have been developed, however most of
these methods only available for infliximab and also not
accessible in everyday clinical practice [24, 25].
The strengths of the present study are the harmonized
monitoring strategy, prospective collection of clinical and
laboratory data. Limitations of the study include the rela-
tively small cohort size, especially in UC. Multiple TDM
samples were available only in few patients. Of note, un-
like infliximab, there are very few studies evaluating serial
TDM measurements in adalimumab therapy. Further
investigation is needed applying serial/routine TDM
measurements to determine the exact role and usability of
routine TDM in adalimumab therapy. In addition,
whether TDM for adalimumab needs to be performed at
trough remains conflictive in current literature and defin-
itely requires more research. Of note, in a very recent
paper by Ward et al. author have shown only little vari-
ation in drug levels during maintenance adalimumab ther-
apy assessed on days 4-6, 7-9 and 13-14 (trough level).
Importantly, drug levels on day 9 were the best predictor
of a therapeutic drug trough level [26].
Conclusions
The present study suggests that ADA development, low
TL and need for dose intensification are frequent during
adalimumab therapy and our results support the use of
selective TDM assessment in IBD patients on adalimu-
mab therapy. ADA positivity was identified as predictor
of loss of response.
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